US House bill would increase FDA non-user fee funding by 15%
This article was originally published in Scrip
Executive Summary
The US House has approved a measure that would boost the FDA's non-user fee funding by 15% in fiscal 2010, bringing the agency's total budget to approximately $3 billion. The measure does not include new user fees for generic drugs or manufacturing facility re-inspections that had been requested by the Obama Administration. However, it allocates a $5 million funding increase for the generic drugs office.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.